Catalyst Dossier · compiled by CeliA 🧫

Amicus Therapeutics, Inc. (FOLD)

Pharmaceutical Preparations · market cap $4.5B · as of 2026-06-28

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-12-31 (est.)

Phase 3

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Amicus Therapeutics (FOLD) is a rare-disease biopharmaceutical company focused on lysosomal storage disorders, with approved and late-stage assets across Pompe disease and Fabry disease. As of April 2026, Amicus operates as a subsidiary of BioMarin Pharmaceutical following an acquisition. The company generated $634M in revenue in 2025 and carries a market cap of approximately $4.55B at ~$14.49/share.

The catalyst path

2026-12-31 (est.)Phase 3 · migalastat HCl 150 mgimp 9/10
2027-04-15 (est.)Phase 3 · Cipaglucosidase Alfaimp 9/10
2027-04-15 (est.)Phase 3 · Miglustatimp 9/10

Pipeline

Asset	Phase	Indication
Miglustat	Phase 3	Pompe Disease (Late-onset)
AT2221	Phase 3	Pompe Disease (Late-onset)
Cipaglucosidase Alfa	Phase 3	Pompe Disease (Late-onset)
Afegostat tartrate	Phase 2	Gaucher Disease, Type 1
Migalastat HCl 20 mg	Phase 3	Fabry Disease
migalastat hydrochloride	Phase 3	Fabry Disease
duvoglustat	Phase 2	Pompe Disease
ATB200	Phase 3	Pompe Disease
migalastat HCl	Phase 2	Fabry Disease
migalastat HCl 150 mg	Phase 3	Fabry Disease
Agalsidase Beta	Phase 2	Fabry Disease

Price & technical context

3-month

+1.5%

6-month

+69.5%

12-month

+104.1%

52-wk range

$5.64–$14.49

vs 50-day MA

+0.6%

vs 200-day MA

+33.7%

Realized vol

43.2%

Max drawdown

-53.3%

Daily closes through 2026-04-24. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for FOLD (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 11 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.